-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Prostate cancer is the most common cancer among men in the UK, with an average of more than 48,000 new cases a year.
about a third of men with non-metastatic desopathic prostate cancer (nmCRPC) underscore the medical needs of these patients within two years.
,000-year-old Nubeqa is supported by the National Institute for Health and Care Excellence (NICE) in the UK in the treatment of non-metastatic desopathic prostate cancer (nmCRPC).
Nubeqa (darolutamide) has been authorized to use it with androgen deprivation therapy (ADT).
, according to Bayer, this is the first treatment recommended by NICE for this allergy.
recommendations are based on the results of the ARAMIS III trial, which evaluated the efficacy and safety of Nubeqa's joint ADT treatment for nmCRPC patients.
in this trial, Nubeqa-co-ADT showed a statistically significant improvement in the primary endpoint of no metastasis survival (MFS), with a medium value of 40.4 months, while placebo-co-ADT was only 18.4 months.
overall survival (OS) data (which showed that patients in the Nubeqa joint ADT group had significantly improved OS and had a 31 percent lower risk of death than placebo-combined ADTs).
